

# Ramzi A Ajjan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3178818/publications.pdf>

Version: 2024-02-01

154  
papers

8,324  
citations

61984

43  
h-index

53230

85  
g-index

160  
all docs

160  
docs citations

160  
times ranked

10135  
citing authors

#	ARTICLE	IF	CITATIONS
1	Total plasma magnesium, zinc, copper and selenium concentrations in obese patients before and after bariatric surgery. <i>BioMetals</i> , 2023, 36, 241-253.	4.1	4
2	Associations Between Erythrocyte Membrane Fatty Acid Compositions and Biomarkers of Vascular Health in Adults With Type 1 Diabetes With and Without Insulin Resistance: A Cross-Sectional Analysis. <i>Canadian Journal of Diabetes</i> , 2022, 46, 111-117.	0.8	3
3	Application of Machine Learning to Assess Interindividual Variability in Rapid-Acting Insulin Responses After Subcutaneous Injection in People With Type 1 Diabetes. <i>Canadian Journal of Diabetes</i> , 2022, 46, 225-232.e2.	0.8	2
4	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	13.7	180
5	Risk factors associated with mortality in individuals with type 2 diabetes following an episode of severe hypoglycaemia. Results from a randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412110674.	2.0	1
6	Purification and Analysis of Circulating Lipid Particles. <i>Methods in Molecular Biology</i> , 2022, 2419, 193-212.	0.9	1
7	Diabetes mellitus and perioperative outcomes: a scoping review of the literature. <i>British Journal of Anaesthesia</i> , 2022, 128, 817-828.	3.4	10
8	Affinity purification of fibrinogen using an Affimer column. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130115.	2.4	0
9	Non-Traditional Pathways for Platelet Pathophysiology in Diabetes: Implications for Future Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4973.	4.1	1
10	Interindividual variability in average <sc>glucose&sc>glycated haemoglobin</sc> relationship in type 1 diabetes and implications for clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1779-1787.	4.4	9
11	Glucose variability is associated with an adverse vascular profile but only in the presence of insulin resistance in individuals with type 1 diabetes: An observational study. <i>Diabetes and Vascular Disease Research</i> , 2022, 19, 147916412211032.	2.0	4
12	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. <i>Haematologica</i> , 2021, 106, 1616-1623.	3.5	9
13	Lipidomic profiling of plasma free fatty acids in type-1 diabetes highlights specific changes in lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2021, 1866, 158823.	2.4	17
14	Improving outcome prediction in individuals with colorectal cancer and diabetes by accurate assessment of vascular complications: Implications for clinical practice. <i>European Journal of Surgical Oncology</i> , 2021, 47, 999-1004.	1.0	7
15	A Kinetic Model for Glucose Levels and Hemoglobin A1c Provides a Novel Tool for Individualized Diabetes Management. <i>Journal of Diabetes Science and Technology</i> , 2021, 15, 294-302.	2.2	20
16	Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries. <i>The Cochrane Library</i> , 2021, 2021, CD013281.	2.8	2
17	Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: Beyond glycated haemoglobin. <i>Diabetic Medicine</i> , 2021, 38, e14529.	2.3	24
18	Antithrombotic therapy in diabetes: which, when, and for how long?. <i>European Heart Journal</i> , 2021, 42, 2235-2259.	2.2	29

#	ARTICLE	IF	CITATIONS
19	Estimated glucose disposal rate as a candidate biomarker for thrombotic biomarkers in T1D: a pooled analysis. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2417-2426.	3.3	7
20	PAI-1 in Diabetes: Pathophysiology and Role as a Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3170.	4.1	38
21	Metformin: Is it Still the First Line in Type 2 Diabetes Management Algorithm?. <i>Current Pharmaceutical Design</i> , 2021, 27, 1061-1067.	1.9	11
22	Fibrinolysis in Acute and Chronic Cardiovascular Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 490-505.	2.7	15
23	Accurate prediction of HbA1c by continuous glucose monitoring using a kinetic model with patient-specific parameters for red blood cell lifespan and glucose uptake. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110137.	2.0	8
24	Personal Glycation Factors and Calculated Hemoglobin A1c for Diabetes Management: Real-World Data from the Diabetes Prospective Follow-up (DPV) Registry. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 452-459.	4.4	13
25	Exploring determinants of self-management in adults with severe mental illness: a qualitative evidence synthesis. <i>BJPsych Open</i> , 2021, 7, S13-S13.	0.7	2
26	Elimination of fibrin $\hat{I}^3$ -chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2103226118.	7.1	10
27	Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6916.	4.1	12
28	Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?. <i>Drugs</i> , 2021, 81, 1365-1371.	10.9	19
29	Addressing shortfalls of laboratory HbA1c using a model that incorporates red cell lifespan. <i>ELife</i> , 2021, 10, .	6.0	11
30	Reduction in cardiovascular mortality following severe hypoglycemia in individuals with type 2 diabetes: the role of a pragmatic and structured intervention. <i>Cardiovascular Diabetology</i> , 2021, 20, 18.	6.8	8
31	Prenatal and Postpartum Maternal Iodide Intake from Diet and Supplements, Urinary Iodine and Thyroid Hormone Concentrations in a Region of the United Kingdom with Mild-to-Moderate Iodine Deficiency. <i>Nutrients</i> , 2021, 13, 230.	4.1	10
32	Albumin-mediated alteration of plasma zinc speciation by fatty acids modulates blood clotting in type-2 diabetes. <i>Chemical Science</i> , 2021, 12, 4079-4093.	7.4	16
33	Fibrinogen $\hat{I}^{\pm}$ C-subregions critically contribute blood clot fibre growth, mechanical stability, and resistance to fibrinolysis. <i>ELife</i> , 2021, 10, .	6.0	13
34	Exploring the facilitators, barriers, and strategies for self-management in adults living with severe mental illness, with and without long-term conditions: A qualitative evidence synthesis. <i>PLoS ONE</i> , 2021, 16, e0258937.	2.5	15
35	Fibrinogen and Antifibrinolytic Proteins: Interactions and Future Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12537.	4.1	6
36	Use of continuous glucose monitoring trend arrows in the younger population with type 1 diabetes. <i>Diabetes and Vascular Disease Research</i> , 2021, 18, 147916412110621.	2.0	6

#	ARTICLE	IF	CITATIONS
37	A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control. <i>Cardiovascular Diabetology</i> , 2021, 20, 238.	6.8	2
38	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020, 41, 255-323.	2.2	2,811
39	Prescribing diabetes medication for cardiovascular risk reduction in patients admitted with acute coronary syndromes: a survey of cardiologists' attitudes and practice. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 194-196.	3.0	10
40	The use of sodium-glucose cotransporter 2 inhibitors in the inpatient setting: Is the risk worth taking?. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 883-891.	1.5	30
41	Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. <i>Cardiovascular Diabetology</i> , 2020, 19, 3.	6.8	31
42	Imbalance between Fibrin Clot Formation and Fibrinolysis Predicts Cardiovascular Events in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 075-082.	3.4	17
43	Rationale and design of the LIBERATES trial: Protocol for a randomised controlled trial of flash glucose monitoring for optimisation of glycaemia in individuals with type 2 diabetes and recent myocardial infarction. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095793.	2.0	2
44	Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 127.	6.8	20
45	Estimated glucose disposal rate demographics and clinical characteristics of young adults with type 1 diabetes mellitus: A cross-sectional pilot study. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412095232.	2.0	11
46	Diabetes and atherothrombosis: The circadian rhythm and role of melatonin in vascular protection. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412092058.	2.0	18
47	Sodium-Glucose Cotransporter 2 Inhibitors in the Era of COVID-19 Pandemic: Is the Benefit to Risk Ratio Still Favorable?. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 745-747.	2.2	12
48	Antiplatelet therapies in diabetes. <i>Diabetic Medicine</i> , 2020, 37, 726-734.	2.3	2
49	The ABO Locus is Associated with Increased Fibrin Network Formation in Patients with Stable Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1248-1256.	3.4	7
50	Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 278-291.	11.4	60
51	Circulating MicroRNA Levels Indicate Platelet and Leukocyte Activation in Endotoxemia Despite Platelet P2Y12 Inhibition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2897.	4.1	17
52	Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. <i>Thrombosis and Haemostasis</i> , 2020, 120, 412-422.	3.4	27
53	Reduced Plasma Magnesium Levels in Type-1 Diabetes Associate with Prothrombotic Changes in Fibrin Clotting and Fibrinolysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 243-252.	3.4	13
54	Prothrombotic fibrin network characteristics in patients with acromegaly: a novel mechanism for vascular complications. <i>European Journal of Endocrinology</i> , 2020, 182, 511-521.	3.7	0

#	ARTICLE	IF	CITATIONS
55	733-P: Postprandial Glucose Variability in People with Type 1 Diabetes Is Individual and Impacted by Physiological and Clinical Parameters. <i>Diabetes</i> , 2020, 69, 733-P.	0.6	2
56	Maturity onset diabetes of the young and fibrin-related thrombosis risk. <i>Diabetes and Vascular Disease Research</i> , 2020, 17, 147916412096304.	2.0	0
57	Role of complement in diabetes. <i>Molecular Immunology</i> , 2019, 114, 270-277.	2.2	31
58	Double diabetes: A distinct high-risk group?. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2609-2618.	4.4	65
59	Glucose, cholesterol and blood pressure in type II diabetes: A longitudinal observational study comparing patients with and without severe mental illness. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2019, 26, 347-357.	2.1	12
60	Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 385-395.	2.0	47
61	Continuous Glucose Monitoring: A Brief Review for Primary Care Practitioners. <i>Advances in Therapy</i> , 2019, 36, 579-596.	2.9	58
62	Total plasma magnesium, zinc, copper and selenium concentrations in type-I and type-II diabetes. <i>BioMetals</i> , 2019, 32, 123-138.	4.1	38
63	Glucose monitoring in diabetes: from clinical studies to real-world practice. <i>Practical Diabetes</i> , 2019, 36, 57-62.	0.3	2
64	The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 189.	3.5	20
65	Flash glucose monitoring improves glycemia in higher risk patients: a longitudinal, observational study under real-life settings. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000611.	2.8	23
66	Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. <i>Platelets</i> , 2019, 30, 148-157.	2.3	25
67	<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019, Volume 12, 2515-2529.	2.4	20
68	Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system. <i>Diabetes and Vascular Disease Research</i> , 2019, 16, 3-12.	2.0	25
69	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. <i>Blood</i> , 2019, 133, 1233-1244.	1.4	17
70	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018, 39, 1672-1686f.	2.2	106
71	Accuracy of flash glucose monitoring and continuous glucose monitoring technologies: Implications for clinical practice. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 175-184.	2.0	66
72	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy. <i>European Heart Journal</i> , 2018, 39, 1078-1085.	2.2	109

#	ARTICLE	IF	CITATIONS
73	Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 37-46.	2.8	181
74	Cardiovascular magnetic resonance measures of aortic stiffness in asymptomatic patients with type 2 diabetes: association with glycaemic control and clinical outcomes. <i>Cardiovascular Diabetology</i> , 2018, 17, 35.	6.8	15
75	Characterizing adults with Type 2 diabetes mellitus and intellectual disability: outcomes of a case-finding study. <i>Diabetic Medicine</i> , 2018, 35, 352-359.	2.3	10
76	Primary vascular prevention: The end of the road for aspirin?. <i>Diabetes and Vascular Disease Research</i> , 2018, 15, 475-476.	2.0	0
77	Should the last be first? Questions and dilemmas regarding early short-term insulin treatment in Type 2 Diabetes Mellitus. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1113-1121.	3.1	7
78	Prolonged Prothrombotic Effects of Antecedent Hypoglycemia in Individuals With Type 2 Diabetes. <i>Diabetes Care</i> , 2018, 41, 2625-2633.	8.6	44
79	Metabolic Control in Type 1 Diabetes: Is Adjunctive Therapy the Way Forward?. <i>Diabetes Therapy</i> , 2018, 9, 1831-1851.	2.5	19
80	Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 1.	2.4	110
81	The Effect of a Simulated Commercial Flight Environment with Hypoxia and Low Humidity on Clotting, Platelet, and Endothelial Function in Participants with Type 2 Diabetes – A Cross-over Study. <i>Frontiers in Endocrinology</i> , 2018, 9, 26.	3.5	2
82	Development of a supported self-management intervention for adults with type 2 diabetes and a learning disability. <i>Pilot and Feasibility Studies</i> , 2018, 4, 106.	1.2	3
83	Thyroid Autoantibodies. <i>Endocrinology</i> , 2018, , 57-87.	0.1	1
84	Managing with Learning Disability and Diabetes: OK-Diabetes – a case-finding study and feasibility randomised controlled trial. <i>Health Technology Assessment</i> , 2018, 22, 1-328.	2.8	11
85	The Relationship between Primary Hyperparathyroidism and Thrombotic Events: Report of Three Cases and a Review of Potential Mechanisms. <i>International Journal of Hematology-Oncology and Stem Cell Research</i> , 2018, 12, 175-180.	0.3	4
86	Vitamin D and diabetes mellitus: Causal or casual association?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 227-241.	5.7	74
87	Vascular risk in obesity: Facts, misconceptions and the unknown. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 2-13.	2.0	26
88	Use of Flash Glucose-Sensing Technology for 12 Months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. <i>Diabetes Therapy</i> , 2017, 8, 573-586.	2.5	141
89	How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, S-27-S-36.	4.4	56
90	An additional bolus of rapid-acting insulin to normalise postprandial cardiovascular risk factors following a high-carbohydrate high-fat meal in patients with type 1 diabetes: A randomised controlled trial. <i>Diabetes and Vascular Disease Research</i> , 2017, 14, 336-344.	2.0	15

#	ARTICLE	IF	CITATIONS
91	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 34.	6.8	95
92	Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2017, 8, 55-73.	2.5	433
93	Diabetes Mellitus, Microalbuminuria, and Subclinical Cardiac Disease: Identification and Monitoring of Individuals at Risk of Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	67
94	Raising awareness of Graves' orbitopathy with early warning cards. <i>Clinical Endocrinology</i> , 2017, 87, 853-859.	2.4	3
95	B $\beta$ 2Arg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes. <i>Thrombosis and Haemostasis</i> , 2017, 117, 295-302.	3.4	3
96	Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. <i>Thrombosis and Haemostasis</i> , 2017, 117, 940-947.	3.4	21
97	The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2017, 12, e0168549.	2.5	35
98	Coronary artery disease-associated genetic variants and biomarkers of inflammation. <i>PLoS ONE</i> , 2017, 12, e0180365.	2.5	25
99	Coronary thrombosis in diabetes: Are we doing enough?. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 445-448.	2.0	0
100	Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 115, 622-631.	3.4	23
101	Sensor and software use for the glycaemic management of insulin-treated type 1 and type 2 diabetes patients. <i>Diabetes and Vascular Disease Research</i> , 2016, 13, 211-219.	2.0	23
102	Hypoglycaemia, thrombosis and vascular events in diabetes. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1099-1101.	1.5	14
103	A Novel and Practical Screening Tool for the Detection of Silent Myocardial Infarction in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3316-3323.	3.6	15
104	Thyroid Autoantibodies. <i>Endocrinology</i> , 2016, , 1-31.	0.1	0
105	An observational study of patient characteristics and mortality following hypoglycemia in the community. <i>BMJ Open Diabetes Research and Care</i> , 2015, 3, e000094.	2.8	45
106	The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls. <i>BMC Endocrine Disorders</i> , 2015, 15, 14.	2.2	47
107	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. <i>Lancet, The</i> , 2015, 385, S57.	13.7	19
108	The Pathogenesis of Hashimoto's Thyroiditis: Further Developments in our Understanding. <i>Hormone and Metabolic Research</i> , 2015, 47, 702-710.	1.5	167

#	ARTICLE	IF	CITATIONS
109	Platelet P2Y <sub>12</sub> Inhibitors Reduce Systemic Inflammation and Its Prothrombotic Effects in an Experimental Human Model. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2562-2570.	2.4	105
110	Supported self-management for adults with type 2 diabetes and a learning disability (OK-Diabetes): study protocol for a randomised controlled feasibility trial. <i>Trials</i> , 2015, 16, 342.	1.6	18
111	Aspirin therapy is associated with less compact fibrin networks and enhanced fibrinolysis in patients with abdominal aortic aneurysm. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 795-801.	3.8	14
112	IL-14 and IL-16 are expressed in the thyroid of patients with either Graves' disease or Hashimoto's thyroiditis. <i>Clinical Endocrinology</i> , 2015, 83, 726-732.	2.4	9
113	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2014, 112, 1142-1150.	3.4	49
114	The role of lectin-like oxidised low-density lipoprotein receptor-1 in vascular pathology. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 410-418.	2.0	12
115	Effect of hypoglycaemia on thrombosis and inflammation in patients with type 2 diabetes. <i>Lancet</i> , The, 2014, 383, S35.	13.7	6
116	Insulin Resistance and Cardiovascular Risk Marker Evaluation in Morbid Obesity 12 Months After Bariatric Surgery Compared to Weight-Matched Controls. <i>Obesity Surgery</i> , 2014, 24, 349-358.	2.1	8
117	Glucokinase MODY and Implications for Treatment Goals of Common Forms of Diabetes. <i>Current Diabetes Reports</i> , 2014, 14, 559.	4.2	22
118	Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. <i>Diabetologia</i> , 2014, 57, 1737-1741.	6.3	43
119	Platelet count, platelet turnover and fibrin clot structure in patients with coronary artery disease. <i>Thrombosis Research</i> , 2014, 133, 1161-1163.	1.7	5
120	Polycystic ovary syndrome has no independent effect on vascular, inflammatory or thrombotic markers when matched for obesity. <i>Clinical Endocrinology</i> , 2013, 79, 252-258.	2.4	28
121	Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. <i>Blood</i> , 2013, 122, 134-142.	1.4	79
122	Fibrin Clot Structure and Platelet Aggregation in Patients with Aspirin Treatment Failure. <i>PLoS ONE</i> , 2013, 8, e71150.	2.5	32
123	Gender-Specific Alterations in Fibrin Structure Function in Type 2 Diabetes: Associations with Cardiometabolic and Vascular Markers. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E2282-E2287.	3.6	51
124	Complement C3 is a novel plasma clot component with anti-fibrinolytic properties. <i>Diabetes and Vascular Disease Research</i> , 2012, 9, 216-225.	2.0	79
125	Thyroid Dysfunction and Fibrin Network Structure: A Mechanism for Increased Thrombotic Risk in Hyperthyroid Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1463-1473.	3.6	47
126	Effects of MASP-1 of the Complement System on Activation of Coagulation Factors and Plasma Clot Formation. <i>PLoS ONE</i> , 2012, 7, e35690.	2.5	99



#	ARTICLE	IF	CITATIONS
127	A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. <i>Diabetologia</i> , 2012, 55, 1103-1113.	6.3	94
128	Clot Architecture Is Altered in Abdominal Aortic Aneurysms and Correlates With Aneurysm Size. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2011, 31, 3004-3010.	2.4	55
129	Review article: Coagulation and fibrinolysis in diabetes. <i>Diabetes and Vascular Disease Research</i> , 2010, 7, 260-273.	2.0	186
130	Thyroid Autoantibody Measurement. <i>Growth Hormone</i> , 2010, , 109-124.	0.2	3
131	Effects of Aspirin on Clot Structure and Fibrinolysis Using a Novel In Vitro Cellular System. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 712-717.	2.4	97
132	Cardiovascular disease and heritability of the prothrombotic state. <i>Blood Reviews</i> , 2009, 23, 67-78.	5.7	20
133	The cardiovascular safety of rosiglitazone. <i>Expert Opinion on Drug Safety</i> , 2008, 7, 367-376.	2.4	28
134	Techniques to quantify TSH receptor antibodies. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 461-468.	2.8	42
135	Confusion over thiazolidinedione-induced heart failure: need for a better definition of heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2008, 6, 623-627.	1.5	5
136	Common variation in the C-terminal region of the fibrinogen $\beta^2$ -chain: effects on fibrin structure, fibrinolysis and clot rigidity. <i>Blood</i> , 2008, 111, 643-650.	1.4	71
137	Coagulation and atherothrombotic disease. <i>Atherosclerosis</i> , 2006, 186, 240-259.	0.8	81
138	Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. <i>European Heart Journal</i> , 2006, 28, 540-545.	2.2	102
139	Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. <i>Diabetes and Vascular Disease Research</i> , 2006, 3, 147-158.	2.0	57
140	New insights into antibody-mediated hyperthyroidism. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 67-81.	2.4	3
141	Complement C3 and C-reactive protein levels in patients with stable coronary artery disease. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1048-1053.	3.4	59
142	Role of clotting factors and fibrin structure in predisposition to atherothrombotic disease. <i>Expert Review of Cardiovascular Therapy</i> , 2005, 3, 1047-1059.	1.5	10
143	New understanding of the role of cytokines in the pathogenesis of Graves's™ ophthalmopathy. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 237-245.	3.3	40
144	Cytokines in Thyroid Autoimmunity. <i>Autoimmunity</i> , 2003, 36, 351-359.	2.6	68

#	ARTICLE	IF	CITATIONS
145	Irish endocrine society: 23rd annual meeting. Irish Journal of Medical Science, 1998, 167, 2-10.	1.5	0
146	Regulation and tissue distribution of the human sodium iodide symporter gene. Clinical Endocrinology, 1998, 49, 517-523.	2.4	80
147	A new chemiluminescent assay for the rapid detection of thyroid stimulating antibodies in Graves' disease. Clinical Endocrinology, 1998, 49, 577-581.	2.4	49
148	The sodium iodide symporter gene and its regulation by cytokines found in autoimmunity. Journal of Endocrinology, 1998, 158, 351-358.	2.6	98
149	Analysis of the T-cell receptor Valpha repertoire and cytokine gene expression in Sjogren's syndrome. Rheumatology, 1998, 37, 179-185.	1.9	40
150	The Modulation of the Human Sodium Iodide Symporter Activity by Graves' Disease Sera. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1217-1221.	3.6	51
151	Detection of IL-12, IL-13, and IL-15 Messenger Ribonucleic Acid in the Thyroid of Patients with Autoimmune Thyroid Disease. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 666-669.	3.6	49
152	Cytokines and thyroid function. Advances in Neuroimmunology, 1996, 6, 359-386.	1.8	81
153	Intrathyroidal cytokine gene expression in Hashimoto's thyroiditis. Clinical and Experimental Immunology, 1996, 105, 523-528.	2.6	93
154	The relative contribution of diurnal and nocturnal glucose exposures to HbA1c in type 1 diabetes males: a pooled analysis. Journal of Diabetes and Metabolic Disorders, 0, , 1.	1.9	2